XVARY Composite Score
48
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Cardiff Oncology is testing onvansertib, an oral cancer drug, across several aggressive cancers.
How it gets paid
Last year Cardiff Oncology made $593K in revenue. Onvansertib collaboration was the main engine at $313K, or 53% of sales.
Why growth slowed
Revenue fell 13.2% last year. The $350K quarter matters because it shows how small the business base still is.
What just happened
$350K of quarterly revenue and -$0.58 EPS show a company still living on clinical hope.
At a Glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
-$0.69 fy2025 eps est
$2B fy2026 rev est
N/a operating margin
XVARY composite: 48/100 — below average
What They Do
Cardiff Oncology is testing onvansertib, an oral cancer drug, across several aggressive cancers.
PLK1 inhibition → blocking a cell-division protein → so what: one target can matter in several cancers. Onvansertib has a 24-hour half-life, so your dose lasts a full day. Cardiff has 32 employees, not 3,200, while it tries to run multi-cancer trials.
How They Make Money
$593K
annual revenue · their business grew -13.2% last year
Onvansertib collaboration
$313K
Research grants
$140K
Development services
$100K
Other revenue
$40K
The Products That Matter
Plk1 inhibitor in Phase 2
Onvansertib
1 lead asset · $127M equity story
this is the story. the company has just $593K of annual revenue, so most of what you are underwriting sits inside one oncology program.
lead asset
Pre-commercial development platform
Clinical pipeline
$593K revenue · still early
the current operating base is tiny. $593K in annual revenue means the pipeline matters far more than any existing business line.
pre-revenue reality
Key Numbers
$593K
annual revenue
That is tiny next to a $127M market cap. The stock is priced like a story, not a sales machine.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Losses dwarf revenue by an absurd margin. That is what a trial-stage company looks like when the product has not turned into sales.
$0M
long-term debt
No debt means no lender pressure. It does not mean you avoid dilution.
32
employees
A 32-person team is trying to run multi-cancer trials. That is lean, and it leaves little room for error.
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
$350K of quarterly revenue and -$0.58 EPS show a company still living on clinical hope.
Revenue rose 192% from the prior year quarter, but the base was tiny. Annual revenue still fell 13.2%, and the company kept losing money.
$350K
revenue
-$0.58
eps
13.2%
revenue Vs. last year
the number that mattered
The $350K quarter matters because it shows how small the business base still is.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The top risk is Phase 2 failure for onvansertib.
Med
Clinical trial disappointment
There is one lead asset carrying most of the story. If Phase 2 data in colorectal or pancreatic cancer disappoints, the thesis takes a direct hit.
With only $593K of annual revenue, there is almost no operating business here to soften a bad readout.
Med
Commercial proof is still missing
The company generated $593K of revenue last year and that figure fell 13.2% from the prior year. You are not buying proven demand today.
That gap between current sales and a $127M market cap makes valuation extremely sensitive to future expectations.
Med
The stock moves like a catalyst vehicle
A 1.45 beta and a 5 / 100 price stability score tell you this name can swing hard around updates, sentiment, or financing fears.
The 52-week range runs from $1 to $5. Same company. Very different implied outcomes.
With just $593K of annual revenue, most of the current equity value lives in one clinical narrative — and narratives break faster than operating businesses.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Catalyst
CRDF-004 data is the whole calendar
The ongoing randomized Phase 2 CRDF-004 study is the clearest event that can move the stock from story to evidence.
Metric
$593K revenue versus $127M market cap
That gap is the snapshot in one line. If you own this, you are paying for optionality, not a scaled business.
Risk
Single-asset dependence
One lead drug candidate means one disappointing update can reset the entire valuation framework.
Trend
Price behavior still says speculation
The stock sits at $1.99 inside a $1–$5 range, with 1.45 beta and 5 / 100 price stability. That is not calm ownership.
Analyst Rankings
earnings predictability
45 / 100
The score says reported results are hard to model. In human-speak, analysts do not have a stable operating machine to forecast here.
risk profile
3
Risk rank 3 puts the balance sheet around the middle of the pack. Better than a distressed biotech, not strong enough to erase clinical risk.
price stability
5 / 100
A 5 / 100 stability score is a warning label. The stock can move violently even when the underlying business barely changes.
Source: institutional data
Institutional Activity
institutional ownership data for CRDF is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$2
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive